TL;DR
This paper presents a novel, cost-effective method for producing therapeutic antibodies with precisely controlled glycosylation patterns. By combining in-vivo deglycosylation in plants with in-vitro chemoenzymatic remodeling, they created a uniform glycoform of rituximab that shows enhanced therapeutic activity compared to the original drug. This approach promises to reduce manufacturing costs and enable customized antibody therapeutics.
What Problem Does This Paper Address?
Therapeutic proteins, especially monoclonal antibodies, are often glycosylated, meaning sugar molecules are attached to them. This glycosylation is crucial for their stability, efficacy, and how long they last in the body. However, current manufacturing methods, often using mammalian cell lines like CHO cells, result in a heterogeneous mix of glycosylation patterns. This "glycoform heterogeneity" makes it difficult to ensure consistent drug quality, efficacy, and safety. While in-vitro methods exist to create uniform glycoforms, they are often expensive and don't integrate well with large-scale production. The challenge, therefore, is to develop a scalable, cost-effective method to produce therapeutic antibodies with precisely defined and homogeneous glycosylation.
Methods
The researchers developed a two-step approach:
- In-vivo Deglycosylation in Plants: They used Nicotiana benthamiana (a common lab plant) as a host for expressing rituximab. Crucially, they co-expressed rituximab with an enzyme called Endoglycosidase H (EndoH). EndoH was engineered to be retained in the plant's endoplasmic reticulum (ER), where it cleaves off the complex N-glycans that form on the antibody, leaving behind a single N-acetylglucosamine (GlcNAc) residue. This creates a "deglycosylated" antibody that serves as a clean substrate for the next step. This in-vivo approach simplifies the process by performing the initial deglycosylation within the plant itself, avoiding a separate in-vitro step.
- In-vitro Chemoenzymatic Remodeling: The deglycosylated rituximab was then purified and subjected to an in-vitro reaction. Using an engineered endoglycosidase S mutant (EndoS D233Q), they attached a pre-defined complex glycan structure (specifically, a Gal2GlcNAc2Man3GlcNAc2 or A2G2 glycoform, which is human-like and afucosylated) onto the exposed GlcNAc residue. This process, called transglycosylation, results in a homogeneous glycoform.
Datasets
Not discussed in the paper. The study focuses on the development and characterization of a specific therapeutic antibody glycoform.
Key Insights and Ideas
- Plant-based production as a scalable and cost-effective platform: The study demonstrates that plants can be engineered to produce therapeutic proteins with a simplified glycosylation profile, offering a viable alternative to traditional mammalian cell culture.
- Integrating deglycosylation into the host system: Performing the initial deglycosylation within the plant cell (in-vivo) significantly streamlines the overall process, reducing the complexity and cost associated with separate in-vitro deglycosylation steps.
- Achieving precise glycan control: The combination of in-vivo deglycosylation and in-vitro chemoenzymatic remodeling allows for the creation of a single, defined glycoform, eliminating heterogeneity.
- Afucosylation is key for enhanced ADCC: The resulting afucosylated A2G2 glycoform of rituximab showed significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), a critical mechanism for antibody-based cancer therapies.
- Plant-specific glycans are successfully eliminated: The method effectively removes plant-specific sugars like α-1,3-fucose and β-1,2-xylose, which can be immunogenic in humans.
Key Results
- High expression levels: Rituximab was expressed at high levels in Nicotiana benthamiana (379 mg/kg of plant biomass).
- Successful in-vivo deglycosylation: Mass spectrometry confirmed the removal of complex glycans, leaving a single GlcNAc residue.
- Uniform A2G2 glycoform produced: The chemoenzymatic remodeling successfully generated a homogeneous A2G2 glycoform of rituximab.
- Similar binding affinity: The remodeled antibody (NbRTXA2G2) showed comparable binding affinity to the CD20 antigen as the innovator product, Rituxan®.
- Significantly enhanced ADCC: NbRTXA2G2 demonstrated a 5.8-fold increase in ADCC response compared to Rituxan® when using high-affinity effector cells.
- Cost-effectiveness potential: The plant-based approach and simplified process are highlighted as having the potential to reduce manufacturing costs.
Limitations and Future Work
- Hemiglycosylation: The study notes that a certain degree of hemiglycosylation (partial glycosylation) was observed on rituximab produced in plants. The biological reasons for this are not fully understood and require further investigation.
- Expression Optimization: The authors are initiating expression optimization to improve deglycosylation efficiency in planta and to develop a scale-up strategy.
- Broader Application: While rituximab was used as a model, the approach is presented as a general strategy for glycan remodeling of therapeutic antibodies, suggesting future work could involve applying this to other antibody targets.
- Further Characterization: While promising, further systematic analysis of the upstream and downstream processes will be reported as it is completed.
Summary updated